# NCT02621151 (NCT02621151)

> Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02621151
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: NYU Langone Health
- Conditions: Muscle-invasive Urothelial Cancer of the Bladder
- Interventions: Pembrolizumab; Transurethral Resection of Bladder Tumor; Gemcitabine; External Beam Radiation Therapy
- Enrollment: 60
- Primary outcome: Percentage of Participants Who Achieved Two-year Bladder-intact Disease-free Survival

## Indexed commentary on NCT02621151 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02621151